Search


PDF Archive search engine
Last database update: 17 May at 09:38 - Around 76000 files indexed.


Show results per page

Results for «renal»:


Total: 70 results - 0.058 seconds

38105d-str-lat-clinical-fellow-in-renal-medicine 100%

STR LAT/CLINICAL FELLOW IN RENAL MEDICINE NEW SOUTH GLASGOW UNIVERSITY HOSPITAL INFORMATION PACK REF NO:

https://www.pdf-archive.com/2016/09/05/38105d-str-lat-clinical-fellow-in-renal-medicine/

05/09/2016 www.pdf-archive.com

GLOTZ Denis 99%

thesis in Immunology, Université Paris VI, Paris 1992 Diplome d'Habilitation à Direction de Recherches Université Paris VI, Paris 1994 Professor of Nephrology, Université Paris VI, Paris Post-doctoral Training -Internships and residencies 1979-1984 Interne des Hopitaux de Paris 1987-1991 Chef de clinique-Assistant des Hopitaux, Department of Nephrology, Hopital Broussais, Paris 1991-1994 Praticien Hospitalo-Universitaire, Department of Nephrology, Hopital Broussais, Paris -Research fellowship 1984-1986 Medical Biology Institute, La Jolla, CA 1986-1987 University of California San Diego, CA Academic Appointment 1994-2004 Professor of Nephrology, Université Paris VI, Paris 2004-present Professor of Nephrology, Université Paris VII, Paris Hospital Appointment 1988-2000 Head, Renal Transplant Unit, Service de Néphrologie Hopital Broussais, Paris 2000-2004 Head, Renal Transplant Unit, Service de Néphrologie Hopital Européen Georges Pompidou 2004-present Chief, Departement of Nephrology and Renal Transplantation, Hopital Saint-Louis, Paris Research Activities 1988-2004 Head, Transplant Immunology group, Unit U 430, INSERM 2004-present Head, Transplant Immunology group, Unit U 662, INSERM Societies American Society of Nephrology, European Dialysis and transplantation Association, French Society of Immunology, French Society of Nephrology, French Society of Transplantation Committees Assignments 1998-1994 Councilor, Board of Faculté de Medecine Broussais-Hotel Dieu 1993-present Member, regulatory Committee for stable blood-derived products, Agence du Médicament, France 1994-present Member, National Pharmacovigilance Committee, Agence du Médicament, France 1995-present Councilor, French Society of Transplantation 2010:

https://www.pdf-archive.com/2016/09/05/glotz-denis/

05/09/2016 www.pdf-archive.com

VAERS Results Form shu 91%

MEASLES + MUMPS + RUBELLA (MMR II) (26) It was reported in a published article that a 22 year old Indian male patient with a history of an episode of measles­related immune thrombocytopenic purpura (ITP) at the age of 4 years (despite treatment with plasma exchange, his renal failure progressed and he remained dialysis dependent) was vaccinated with a dose of MMR as part of the requirements for overseas travel. Subsequently, the patient developed diarrhea­ negative haemolytic uraemic syndrome (HUS). Renal biopsy revealed virtually complete obliteration of the arcuate artery by smooth muscle proliferation and mocoid change, with negative immunofluorescence studies.

https://www.pdf-archive.com/2016/03/28/vaers-results-form-shu/

28/03/2016 www.pdf-archive.com

Kidney 2018 Brochure 87%

https://kidney.conferenceseries.com/abstract-submission.php Abstract Categories Awards Best poster award Young research forum award Kidney 2018 Kidney • Acute Kidney Injury • CKD -Mineral and Bone Disorders • Chronic Kidney Disease • Kidney and Bladder stones • Dialysis and Renal Care • Urology/Urinary Tract Infections • Kidney Transplantation • Geriatric-Genetic Kidney Diseases • Pediatric Nephrology • Renal Nutrition • Kidney Cancer • Nephrology Nursing • Diabetic Kidney Disease • Diagnosis of Kidney Diseases • Cardiovascular Impacts of Kidney Disease • Renal Pathology-Immunology • Glomerular-Tubulointerstitial Disorders • Drugs for Kidney Diseases • Fluid, Electrolytes, Acid-Base Disorders About Conference Kidney 2018 Video presentation /E poster Video presentation and E poster opportunity facilitated for eminent scholars who are unable to attend the conference.

https://www.pdf-archive.com/2018/05/11/kidney-2018brochure/

11/05/2018 www.pdf-archive.com

PROPECTO INTELENCE CHILE 86%

Personas de edad avanzada La información de la que se dispone es limitada para este grupo (véase secciones 4.4 y 5.2), sin embargo se debe ajustar la dosis cuando existe deterioro de la función renal, hepática o cardíaca.

https://www.pdf-archive.com/2016/09/20/propecto-intelence-chile/

20/09/2016 www.pdf-archive.com

Ox stress Pyelonephritis 85%

Acute pyelonephritis is an ascending Materials urinary tract infection that has reached the renal pelvis, usually accompanied by infection within the renal parenchyma.

https://www.pdf-archive.com/2014/01/07/ox-stress-pyelonephritis/

07/01/2014 www.pdf-archive.com

Poster Final.. 85%

Descrição do caso Identificação Hábitos • A.J.O • Masculino • 65 anos • Ex-Fumador (15 UMA) • 2 doses padrão por dia Antecedentes Pessoais Medicação Habitual • Hipertensão Arterial • Diabetes Mellitus tipo 2 • Dislipidemia • Excesso de Peso • Apendicectomia (18 anos) • Metformina 850mg id • Enalapril + Lercanidipina 20+20mg id • Atorvastatina 20mg id Análises sanguíneas Hemograma e Bioquímica sem alterações PCR, VS e LDH normais Ecografia Abdominal e Renal (11.07.2013) Esteatose Hepática Hemangioma Hepático (11mm) Microlitíase Renal Radiografia Abdominal (2013) “(…) Abundante conteúdo fecal no cólon ascendente.

https://www.pdf-archive.com/2017/06/08/poster-final/

07/06/2017 www.pdf-archive.com

PROSPECTO INTELENCE URUGUAY 83%

Insuficiencia renal No se requieren un ajuste especial de la dosis en pacientes con insuficiencia renal (véase Advertencias y precauciones especiales de empleo y Propiedades farmacocinéticas).

https://www.pdf-archive.com/2016/09/19/prospecto-intelence-uruguay/

19/09/2016 www.pdf-archive.com

BetmigaTest 82%

Has not been studied in patients with end-stage renal disease, severe hepatic impairment or severe uncontrolled hypertension and therefore should not be used.

https://www.pdf-archive.com/2013/09/16/betmigatest/

16/09/2013 www.pdf-archive.com

PROSPECTO INTELENCE COLOMBIA 77%

Insuficiencia renal: ... Enfermedad renal.

https://www.pdf-archive.com/2016/09/20/prospecto-intelence-colombia/

20/09/2016 www.pdf-archive.com

ER1015 75%

18:40-18:50 Leonor García Maset (Hospital de Sagunto, Valencia) T4 - Manejo del paciente con trasplante renal en centro no trasplantador.

https://www.pdf-archive.com/2018/05/24/er1015/

24/05/2018 www.pdf-archive.com

PCCU Dosing Handbook 2009 74%

Legend A Adult N Neonate-doses apply to newborn infants until post-conceptional age >38 weeks and post-natal age of >4 weeks C Child I Infant ETT Endotracheally Inh Inhalation IM Intramuscular IO Intraosseus IV Intravenous PNA Post natal age po Oral pr Rectal Renal dose adjust sc Dose requires adjustment in renal insufficiency consult other references subcutaneous 3 Children’s Hospital, London Health Sciences Centre Intended for use in the Paediatric Critical Care Unit (PCCU) Children’s Hospital, London Health Sciences Centre, London, Ontario.

https://www.pdf-archive.com/2015/07/04/pccu-dosing-handbook-2009/

03/07/2015 www.pdf-archive.com

07d0c77d5987f908461f9f7c33741941 72%

• Apply Level 1 evidence on the use of chemotherapy in men with newly diagnosed metastatic prostate cancer • Apply Level 1 evidence on the use of active surveillance for men with newly diagnosed low or intermediate risk prostate cancer • Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced renal cancer • Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced bladder cancer • Apply level 1 evidence on the optimal approach and sequencing of new agents in the management of advanced testicular cancer WHO SHOULD ATTEND:

https://www.pdf-archive.com/2018/07/15/07d0c77d5987f908461f9f7c33741941/

15/07/2018 www.pdf-archive.com

EDITAL DO PROCESSO SELETIVO LAU-UFPE 2018-2019 71%

Noções Básicas de Transplante Renal 6. ... Litíase Renal 9.

https://www.pdf-archive.com/2018/04/21/edital-do-processo-seletivo-lau-ufpe-2018-2019/

21/04/2018 www.pdf-archive.com

Hypertonic Dehydration FSI 69%

(2) diseases of the regulating organs (enteritis, renal insufficiency, burns, respiratory insufficiency);

https://www.pdf-archive.com/2015/01/07/hypertonic-dehydration-fsi/

07/01/2015 www.pdf-archive.com

ANESTHESIA for Labor and Delivery 63%

 Rising hormonal levels (progesterone, estrogen, chorionic, gonadotropin, etc)  The enlarging uterus Physiologic Changes with Pregnancy  Cardiovascular  Respiratory  Neurologic  Hematologic  Renal  Gastrointestinal Cardiovascular Changes with Pregnancy 1.

https://www.pdf-archive.com/2014/02/14/anesthesia-for-labor-and-delivery/

14/02/2014 www.pdf-archive.com

7148317 166 English CV(CH Liao) 63%

The Contribution of MMP-7 Promoter Polymorphisms in Renal Cell Carcinoma.

https://www.pdf-archive.com/2019/04/23/7148317166englishcvchliao/

23/04/2019 www.pdf-archive.com

TA Metabolic 50pax 20160712 62%

Renal Protection B ra n d S t ra te gy We e k 2 016 | H o C h i M i n h C i t y, V i e t n a m New CV death reduction Simplicity # Metabolic Powerful HbA1c reduction Cardioprotection

https://www.pdf-archive.com/2016/07/13/ta-metabolic-50pax-20160712/

13/07/2016 www.pdf-archive.com

Common Medical Abbreviation 62%

cute Respiratory istress yndrome cute Renal Failure ARM :

https://www.pdf-archive.com/2016/12/10/common-medical-abbreviation/

10/12/2016 www.pdf-archive.com

肾癌治疗的方法和类型 62%

肾癌治疗的方法和类型 肾癌的治疗取决于疾病的类型和阶段。 手术 手术是最常见的治疗方法,因为肾癌并不经常对化疗和放疗作出反应。手术复杂性可以通 过 RENAL Nephrometry 评分系统来估计。如果癌症没有传播,通常会通过手术去除。在某 些情况下,这涉及去除整个肾脏,但是大多数肿瘤可以部分去除以消除肿瘤并保留肾脏的 剩余正常部分。手术并不总是可能的 - 例如患者可能有其他妨碍它的医疗条件,或者癌症 可能在身体周围传播,医生可能无法将其移除。目前还没有证据表明,手术后没有已知的 残留疾病即辅助治疗的全身医疗治疗有助于提高肾癌的生存率。如果不能用手术治疗癌 症,则可以使用其他技术,例如冷冻肿瘤或用高温处理。然而,这些尚未被用作肾癌的标 准治疗方法。 药物等生物疗法 其他治疗方案包括生物疗法,如依维莫司,托丝壳,nexavar,索坦 sutent 和 axitinib,使 用免疫治疗,包括干扰素和白细胞介素-2。免疫治疗在 10%至 15%的人中成功。舒尼替尼 是当前辅助治疗标准,与吡罗他尼一起使用;这些治疗常常是依维莫司,阿替克替尼和索拉 非尼。 在第二线设置中,奈韦布班在 2015 年显示了依维莫司治疗晚期清除肾细胞癌的总生存优 势,并获得 FDA 批准, Cabozantinib 也显示了依维莫司的总体生存益处,并于 2016 年被 FDA 批准为二线治疗。与依维莫司联合使用的列伐他汀于 2016 年获得批准,该患者只有一 条先前的血管生成治疗方案。 在 Wilms 肿瘤中,化疗,放疗和手术是接受治疗,取决于疾病诊断阶段。 儿童肾癌 儿童报告的大多数肾癌是 Wilms 肿瘤。当胎儿仍然在子宫中发育时,这些肿瘤可以开始生 长,直到孩子几岁才可能不会出现问题。在 5 岁以下的儿童中,Wilms 肿瘤最常见,但在 大龄儿童或成年人中很少被诊断出。仍然不清楚是什么导致大多数威尔姆斯的肿瘤。最常 见的症状是尿液中的腹部和血液肿胀。 印度抗癌药品更多详情咨询 电话:0091-9205113743 电子邮箱:lifesmarthealthcare@gmail.com 官网:www.apolopharmacy.com

https://www.pdf-archive.com/2018/01/18/untitled-pdf-document-7/

18/01/2018 www.pdf-archive.com

CONVITE AO SIMPÓSIO 61%

Carlos Souza (12:30-13:30) Horário de Almoço 13:30 - Transplante Renal:

https://www.pdf-archive.com/2018/04/18/convite-ao-simpo-sio/

17/04/2018 www.pdf-archive.com

CV ALESSANDRA CROBE 59%

Faa, “Decreasing Podocyte Number during Human Kidney Intrauterine Development.”, American Journal of Physiology – Renal Physiology DOI:

https://www.pdf-archive.com/2015/02/15/cv-alessandra-crobe/

15/02/2015 www.pdf-archive.com